The company released its report — “Dexcom State of Type 2 Report: Access and Attitudes Across the United States” — ahead of the American Diabetes Association’s 85th Scientific Sessions in Chicago. Findings provide insights into perceptions around diabetes technology from more than 400 healthcare professionals and people with type 2 diabetes across the U.S.
San Diego-based Dexcom develops continuous glucose monitoring (CGM) and biosensing technologies. It aims to bring the technology to more people, especially within the diabetes community.
The company earlier this year launched a similar report covering Europe and the Middle East. President and COO Jake Leach spoke to Drug Delivery Business News about the significance of that report in March. The company says the latest report builds on those initial findings with data collected in the U.S.
A look at the findings from Dexcom
Among the takeaways, Dexcom says more than half (59%) of U.S. healthcare providers (HCPs) believe better access to CGM offers the most effective way to help people with type 2 diabetes manage their condition over the next decade. They support CGM as a standard of care as well. The report says 96% of providers agree that it should be the standard of care for individuals on multiple daily insulin injections (MDI). Additionally, 94% agree on CGM becoming the standard of care for those on basal insulin.
U.S. HCPs unanimously support the use of CGM in combination with GLP-1 medications as well. All surveyed recommend it in combination with GLP-1 or SGLT2 medication, Dexcom said. They believe it has the best expected outcomes for patients, while 79% of providers in EMEA agreed.
Dexcom also reports that HCPs believe additional coverage and more educational support can improve CGM access and understanding. Additionally, they say more training for healthcare providers would support Americans with type 2 diabetes. Specifically, 60% said additional funding or budget to cover CGM could increase usage among people with type 2 diabetes.
“The findings of our State of Type 2 Report in the U.S. reaffirm what we’ve always believed to be true: CGM is central to the future of type 2 diabetes care,” said Leach. “To help drive the greatest impact for patients, a continued focus on diabetes education and access to CGMs is needed – and Dexcom is committed to advancing these around the world.”
